Candriam S.C.A. Reduces Stock Holdings in Option Care Health, Inc. (NASDAQ:OPCH)

Candriam S.C.A. lowered its position in Option Care Health, Inc. (NASDAQ:OPCH) by 51.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 135,294 shares of the company’s stock after selling 146,218 shares during the quarter. Candriam S.C.A.’s holdings in Option Care Health were worth $3,139,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of OPCH. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Option Care Health in the third quarter valued at about $206,000. Villere ST Denis J & Co. LLC grew its holdings in shares of Option Care Health by 1.3% in the third quarter. Villere ST Denis J & Co. LLC now owns 1,135,106 shares of the company’s stock valued at $35,529,000 after purchasing an additional 14,439 shares during the period. Atria Investments Inc purchased a new stake in shares of Option Care Health in the third quarter valued at about $213,000. Victory Capital Management Inc. grew its holdings in shares of Option Care Health by 4,432.8% in the third quarter. Victory Capital Management Inc. now owns 1,621,593 shares of the company’s stock valued at $50,756,000 after purchasing an additional 1,585,818 shares during the period. Finally, Geneva Capital Management LLC purchased a new stake in shares of Option Care Health in the third quarter valued at about $24,679,000. Hedge funds and other institutional investors own 98.05% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on the stock. UBS Group assumed coverage on shares of Option Care Health in a research report on Thursday, December 5th. They issued a “neutral” rating and a $26.00 target price on the stock. JMP Securities reaffirmed a “market outperform” rating and issued a $30.00 target price (down previously from $31.00) on shares of Option Care Health in a research report on Friday, January 10th. JPMorgan Chase & Co. upped their target price on shares of Option Care Health from $40.00 to $41.00 and gave the company an “overweight” rating in a research report on Thursday. Bank of America raised shares of Option Care Health from a “neutral” rating to a “buy” rating and upped their target price for the company from $26.00 to $33.00 in a research report on Monday, January 13th. Finally, Barrington Research upped their target price on shares of Option Care Health from $33.00 to $38.00 and gave the company an “outperform” rating in a research report on Thursday, February 27th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $33.00.

Insider Transactions at Option Care Health

In other news, insider Michael Bavaro sold 30,996 shares of the stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $33.26, for a total transaction of $1,030,926.96. Following the sale, the insider now owns 44,974 shares of the company’s stock, valued at approximately $1,495,835.24. This represents a 40.80 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.64% of the company’s stock.

Option Care Health Stock Down 0.7 %

Shares of OPCH opened at $34.01 on Friday. The stock has a market capitalization of $5.62 billion, a PE ratio of 28.58, a P/E/G ratio of 2.30 and a beta of 1.33. Option Care Health, Inc. has a 1 year low of $21.39 and a 1 year high of $34.85. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.32 and a current ratio of 1.73. The company’s 50-day simple moving average is $29.83 and its 200-day simple moving average is $28.18.

Option Care Health Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.